New tetrahydrobenzindoles as potent and selective 5-HT7 antagonists with increased In vitro metabolic stability

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 1, 2003, Pages 61-64

  Kikuchi, Chika ^a   Suzuki, Hisashi ^a   Hiranuma, Toyokazu ^a   Koyama, Masao ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DR 4004; DR 4485; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; 2A (4 (4 PHENYL 1,2,3,6 TETRAHYDROPYRIDYL)BUTYL) 2A,3,4,5 TETRAHYDROBENZO(CD)INDOL 2(1H) ONE; 2A-(4-(4-PHENYL-1,2,3,6-TETRAHYDROPYRIDYL)BUTYL)-2A,3,4,5-TETRAHYDROBENZO(CD)INDOL-2(1H)-ONE; CYCLIC AMP; HALOGEN; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN RECEPTOR;

AEROBIC METABOLISM; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; EMBRYO; HALOGENATION; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; ANIMAL; BIOAVAILABILITY; CELL LINE; CHEMISTRY; DRUG EFFECT; METABOLISM; RADIOASSAY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CYCLIC AMP; DRUG STABILITY; HALOGENS; HUMANS; INDOLES; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037421025     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00842-9     Document Type: Article

References (35)

1. Shen Y., Monsma F.J., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. J. Biol. Chem. 268:1993;18200.
2. Lovenberg T.W., Baron B.M., de Lecea L., Miller J.O., Prosser R.A., Rea M.A., Foye P.E., Rucke M., Slone A.L., Siegel B.W., Danielson P.E., Sutcliffe J.G., Erlander M.G. Neuron. 11:1993;449.
3. Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang L.M., Schwartz J.C. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8547.
4. Plassat J.-L., Amlaiky N., Hen R. Mol. Pharmacol. 44:1993;229.
5. Bard J.A., Zgombick J., Adham N., Vaysse P., Branchek T.A., Weinshank R.L. J. Biol. Chem. 268:1993;23422.
6. Tsou A.-P., Kosaka A., Bach C., Zuppan P., Yee C., Tom L., Alvarez R., Ramsey S., Bonhaus D.W., Stefanich E., Jakeman L., Eglen R.M., Chan H.W. J. Neurochem. 63:1994;456.
7. Leung E., Walsh L.K.M., Pulido-Rios M.T., Eglen R.M. Br. J. Pharmacol. 117:1996;926.
8. Martin G.R., Wilson R.J. Br. J. Pharmacol. 114:1995;383. P.
9. Walsh L.K.M., Pulido-Rios T.M., Hamilton C.D., Wong E.H.F., Eglen R.M., Leung E. FASEB J. 9:1995;5426.
10. Cushing D.J., Zgombick J.M., Nelson D.L., Cohen M.L. J. Pharmacol. Exp. Ther. 277:1996;1560.
11. Sleight A.J., Carolo C., Petit N.; Zwingelstein, C.; Bourson, A. Mol. Pharmacol. 47:1995;99.
12. Sumova A., Maywood E.S., Selvage D., Ebling F.J.P., Hastings M.H. Brain Res. 709:1996;88.
13. Ying S.-W., Rusak B. Brain Res. 755:1997;246.
14. Schwartz W.J. Adv. Int. Med. 38:1993;81.
15. Duncan M.J., Short J., Wheeler D.L. Brain Res. 829:1999;39.
16. Hagan J.J., Price G.W., Jeffrey P., Deeks N.J., Stean T., Piper D., Smith M.I., Upton N., Medhurst A.D., Middlemiss D.N., Riley G.J., Lovell P.J., Bromidge S.M., Thomas D.R. Br. J. Pharmacol. 130:2000;539.
17. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. J. Pharmacol. Exp. Ther. 268:1994;1403.
18. Kikuchi C., Nagaso H., Hiranuma T., Koyama M. J. Med. Chem. 42:1999;533.
19. Kikuchi C., Ando T., Watanabe T., Nagaso H.; Okuno, M.; Hiranuma, T.; Koyama, M. J. Med. Chem. 45:2002;2197.
20. Kikuchi C. M.; Hiranuma, T.; Koyama, M. Bioorg. Med. Chem. Lett. 12:2002;2549.
21. Forbes I.T., Dabbs S., Duckworth D.M., Jennings A.J., King F.D., Lovell P.J., Brown A.M., Collin L., Hagan J. J.; Middlemiss, D, N.; Riley, G. J.; Thomas, D. R.; Upton, N. J. Med. Chem. 41:1998;655.
22. Lovell P.J., Bromidge S.M., Dabbs S., Duckworth D.M., Forbes I.T., Jennings A.J., King F.D., Middlemiss D.N., Rahman S.K., Saunders D.V., Collin L.L., Hagan J.J., Riley G.J., Thomas D.R. J. Med. Chem. 43:2000;342.
23. Linnanen T., Brisander M., Unelius L., Rosqvist S., Nordvall G., Hacksell U., Johansson A.M. J. Med. Chem. 44:2001;1337.
24. The oral bioavailability of compound 1 was <10% in rats.
25. +).
26. 2] were performed on a gently shaking platform maintained at 37 °C. Incubations were started by the addition of substrate and were stopped after 0, 10, 30 and 60 min by addition of DMF. Precipitated proteins were removed by centrifugation and supernatants were injected into the HPLC system to determine the remaining amount of each compound.
27. 7 receptor, but this derivative had lower selectivity than compound 1. See ref 19.
28. Leysen J.E., Niemegeers C.J.E., Van Nueten J.M., Laduron P.M. Mol. Pharmacol. 21:1982;301.
29. Martin G.R., Humphrey P.P.A. Neuropharmacology. 33:1994;261.
30. Domenech T., Beleta J., Palacios J.M. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;328.
31. Wolf W.A., Schultz J.S. J. Neurochem. 69:1997;1449.
32. Millerk W.A., Fletcher P.W., Teitler M. Synapse. 11:1992;58.
33. Boess F.G., Steward L.J., Steele J.A., Liu D., Reid J., Glencorse T.A., Martin I.L. Neuropharmacology. 36:1997;637.
34. Grossman C.J., Kilpatrick G.J., Bunce K.T. Br. J. Pharmacol. 109:1993;618.
35. Monsma F.J. Jr., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Mol. Pharmacol. 43:1993;320.